Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.7852W HIGH $61.85
Volume
13.13 K
Value Traded
259.62 K
Short % Float
3.79%
-1.8%Week
-22.36%1 Month
-30.16%3 Month
-69.97%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
56.08 M
EPS (TTM)
-2.52
P/E Ratio
-
Ent. Value
302.74 M
Total Shares
14.68 M
Float Shares
8.47 M
Insiders
0.03%
Institutions
27.04%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ZEPP Catalyst Timeline
Dated clinical, regulatory and corporate events for Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares
Past FDA Catalysts and PDUFA Decisions
How ZEPP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Zepp Health Corporation is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ZEPP program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Yu PengtaoOfficer (Chief Industrial Designer) | Sell | -4,251 98,491 held | $4.09 | 09/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ZEPP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ZEPP for Q2 2026. | ||||
ZEPP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ZEPP ranks across every disease it competes in
Competitive Position is a premium feature
See how ZEPP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialZEPP News
-ZEPP
Sep 2, 2026▲ +8%on this news
Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for Q2 2026, showing a revenue increase of 6.9% year-over-year to US$63.5 million. Despite the revenue growth, the company experienced a net loss of US$11.3 million, up from US$7.7 million in the previous year, due to foreign-exchange impacts and increased investments in R&D and marketing. The gross margin improved to 37.4%, reflecting a favorable product mix, although challenges remain with supply constraints and rising component costs.
Read more →-ZEPP
Aug 19, 2026Zepp Health Corporation to Report Second Quarter 2026 Financial Results on September 1, 2026
Zepp Health Corporation will report its second quarter 2026 financial results on September 1, 2026. A conference call is scheduled for 9:30 p.m. ET, where management will discuss the results. The call will be accessible via phone and a live webcast. Zepp Health is recognized for its innovative health technology products.
Read more →-ZEPP
Jun 19, 2026Samenvatting: Amazfit introduceert de Helio Strap Pro en brengt bewegingsgegevens van het lichaam naar HYROX- en hybride trainingen
Amazfit has introduced the Helio Strap Pro, designed to enhance movement tracking for HYROX and hybrid training. The new strap aims to provide users with detailed body movement data to improve their training experience. This launch reflects Amazfit's commitment to innovation in fitness technology.
Read more →-ZEPP
Jun 19, 2026Riassunto: Amazfit introduce Helio Strap Pro, offrendo l'intelligenza del movimento indossata per l'allenamento HYROX e ibrido
Amazfit has launched the Helio Strap Pro, designed for HYROX training and hybrid workouts. This new product emphasizes movement intelligence, enhancing the training experience. The strap aims to provide users with advanced insights into their performance during workouts.
Read more →-ZEPP
Jun 19, 2026Amazfit presenta Helio Strap Pro, que aporta inteligencia de movimiento en dispositivos portátiles para el entrenamiento HYROX e híbrido
Amazfit has introduced the Helio Strap Pro, designed for HYROX and hybrid training. However, the article provides minimal information regarding its features or benefits. The lack of details raises questions about the product's functionality and market relevance.
Read more →-ZEPP
Jun 19, 2026Amazfit apresenta o Helio Strap Pro, trazendo inteligência de movimento corporal para treinamento HYROX e híbrido
Amazfit has introduced the Helio Strap Pro, designed to enhance body movement intelligence for HYROX and hybrid training. This new product aims to improve training efficiency and effectiveness. However, further details about its features and market impact are limited.
Read more →-ZEPP
Jun 19, 2026Amazfit stellt das Helio Strap Pro vor und bringt am Körper getragene Bewegungsanalyse in das HYROX- und Hybridtraining
Amazfit has introduced the Helio Strap Pro, which focuses on body-worn motion analysis for HYROX and hybrid training. This new product aims to enhance performance tracking during workouts. Details regarding its features and market availability are yet to be fully disclosed.
Read more →-ZEPP
Jun 18, 2026▼ -7.1%on this newsshared move
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training
Amazfit has introduced the Helio Strap Pro, designed for body-worn movement intelligence in HYROX and hybrid training. However, the article provides minimal details about the product's features or benefits, leaving readers with questions about its market implications.
Read more →-ZEPP
Jun 9, 2026▼ -28.6%on this news
Zepp Health Corporation Reports First Quarter of 2026 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for Q1 2026, showing a revenue increase of 33.8% year-over-year to $51.5 million. The company launched several new products aimed at enhancing user engagement and performance. Despite a seasonal dip in consumer electronics, management expects continued growth in the upcoming quarter, with projected revenues between $63 million and $68 million.
Read more →-ZEPP
May 26, 2026Zepp Health Corporation to Report First Quarter 2026 Financial Results on June 8, 2026
Zepp Health Corporation will report its first quarter 2026 financial results on June 8, 2026. A conference call is scheduled for 9:30 p.m. ET on the same day, allowing stakeholders to access the results and insights. The company continues to lead in the smart wearables market, emphasizing its commitment to health technology.
Read more →-ZEPP
Apr 24, 2026Zepp Health Corporation Files 2025 Annual Report on Form 20-F
Zepp Health Corporation has filed its annual report on Form 20-F for the year ending December 31, 2025. The report is accessible on the company's investor relations website and the SEC's website. Zepp Health, known for its smart wearables, has successfully shipped over 200 million units globally.
Read more →-ZEPP
Mar 16, 2026▼ -22.1%on this news· ran to -33% by day 3
Zepp Health Corporation Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results MILPITAS, Calif. , March 15th 2026 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today announ
Zepp Health Corporation announced its fourth quarter and full year 2025 financial results, highlighting a strong revenue growth of 43% in Q4 reaching US$85.2 million. The gross margin improved to a record high of 40.4%, attributed to a more favorable product mix. Despite an adjusted operating loss of US$2.7 million, the company is optimistic about sustained growth into 2026, supported by strong sales during the holiday seasons and ongoing improvements in capital structure and inventory management.
Read more →-ZEPP
Nov 5, 2025▼ -6%on this news· ran to -40% by day 3
Zepp Health Corporation Reports Third Quarter 2025 Unaudited Financial Results MILPITAS, Calif., November 4th, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today announced its unaud
Zepp Health Corporation reported strong financial results for Q3 2025, with revenues reaching $75.8 million, a 78.5% increase year-over-year. The company achieved breakeven in adjusted operating income and improved gross margins to 38.2%. Key drivers included the successful launch of new products, notably the Amazfit T-Rex 3 Pro. However, the company also faced challenges such as supply constraints and a delay in sales due to a natural disaster.
Read more →-ZEPP
Aug 3, 2025▲ +34%on this news· ran to +87% by day 3
Zepp Health Corporation Reports Second Quarter 2025 Unaudited Financial Results
Zepp Health Corporation reported its second quarter 2025 unaudited financial results, highlighting a 46.2% year-over-year revenue growth primarily driven by Amazfit products. This marks the company's first overall revenue growth since 2021 and reflects successful strategic initiatives. The company expects continued strength in sales for the third quarter, with projections of US$72.0 million to US$76.0 million in revenue. Despite some decline in gross margin and ongoing adjusted operating losses, the firm remains optimistic about future growth stemming from its innovative product pipeline and effective marketing strategies.
Read more →-ZEPP
May 19, 2025Zepp Health Corporation Reports First Quarter 2025 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for the first quarter of 2025, showcasing a 10% year-over-year revenue growth from Amazfit products. Key drivers included the successful launches of new smartwatch models, despite challenges such as net losses and fixed expenses not being fully absorbed during the low sales season. The company highlighted improvements in gross margins and is optimistic about continued sales growth for upcoming product launches, alongside significant adjustments in supply chain strategy. However, there are ongoing supply constraints affecting certain product versions.
Read more →-ZEPP
Mar 26, 2025▼ -6.8%on this news
Zepp Health Corporation Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for the fourth quarter and full year of 2024, indicating robust growth in revenue and gross margin despite prior year declines. The company achieved a 40.2% increase in Q4 revenue compared to the previous quarter, largely driven by the successful launch of the T-Rex 3 smartwatch. However, year-over-year comparisons showed a revenue drop of 28.3%, attributed to different product launch timing and macro headwinds. Zepp's cash position remains strong, with $111 million reported, suggesting potential for future investments.
Read more →-ZEPP
Nov 18, 2024Zepp Health Corporation Reports Third Quarter 2024 Unaudited Financial Results
Zepp Health Corporation announced its unaudited financial results for the third quarter of 2024, reporting revenues of $42.5 million, a decrease of 48.9% from the previous year. Despite a net loss of $13.3 million, the company experienced a positive trend with a 10% increase in Amazfit branded sales and achieved the highest gross margin in its history. Key product launches, particularly the T-Rex3 smartwatch, have been well-received, and the company is optimistic about sustained growth moving forward with a strong product pipeline and strategic direction.
Read more →-ZEPP
Oct 2, 2024Zepp Regains Compliance with NYSE Minimum Price Continued Listing Criterion
Zepp Health Corporation announced that it has regained compliance with the NYSE's minimum price continued listing criterion, following an earlier notification that its share price had fallen below compliance standards. The NYSE communicated this positive change in a letter dated October 2, 2024. This development marks a recovery for the company after it was previously below the compliance threshold due to a low average closing price of its American depositary shares over a consecutive trading period. Zepp Health continues to operate as a prominent player in the smart wearables and health technology market.
Read more →-ZEPP
Sep 6, 2024Zepp Health Corporation Announces Plan to Implement ADS Ratio Change
Zepp Health Corporation has announced a change in the ratio of its American depositary shares (ADSs) to Class A ordinary shares. The new ratio will increase from 1 ADS representing 4 shares to 1 ADS representing 16 shares, effectively initiating a one-for-four reverse ADS split. The change is set to take effect around September 16, 2024, subject to SEC approval. The company emphasizes that this adjustment will not affect the underlying ordinary shares, although it introduces complexities regarding fractional ADSs.
Read more →-ZEPP
Sep 3, 2024Zepp Health Corporation Announces Board Changes
Zepp Health Corporation has announced new appointments to its board of directors, effective September 1, 2024. Mr. Alain Lam, Mr. Mike Yan Yeung, and Mr. Meihui Fan join the board, bringing extensive experience in finance, operations, and technology. Resigning directors include Mr. De Liu, Ms. Yunfen Lu, and Mr. Xiaojun Zhang, with some continuing their roles in the company. The new appointments are expected to strengthen the company's leadership as it navigates the health technology sector.
Read more →About Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares
BIOPHARMAWATCH ELITE PLUS
Trade the next ZEPP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime